Advance notice to innovator for launch at risk is compulsory???

Recently, the U.S. District Court for the Southern District of New York ruled that a generic player may not be required to submit or provide advance notice to the innovator of their intent to launch at-risk a competing product in Teva et al. v. Sandoz, Inc., 08-7611 (S.D.N.Y. October 12, 2010).
This decision is noteworthy in that it contrasts with the practice in the District Court of New Jersey where at least one generic company has been ordered to provide advance notice to the brand companies of an impending at-risk launch.
For full details click here